AstraZeneca’s breast cancer drug Etcamah (camizestrant) has failed to meet the primary objective of a late-stage clinical trial, dealing a setback to the company’s efforts to expand the treatment’s use.
The Phase 3 SERENA-4 trial tested Etcamah in combination with Pfizer’s cancer drug palbociclib in patients with previously untreated, estrogen receptor-positive and HER2-negative advanced breast cancer.
Editorial Insight
Key Highlights
Important points readers should notice.
Issue/Event: AstraZeneca’s Etcamah missed the primary endpoint in a Phase 3 breast cancer trial.
Location: Global clinical trial
Authority/Organisation: AstraZeneca
Action Taken: Company reported the SERENA-4 results after the trial failed to show a statistically significant progression-free survival benefit.
Impact: The result limits the immediate expansion opportunity for Etcamah in the tested first-line advanced breast cancer setting.
The combination showed a numerical improvement in progression-free survival compared with the standard treatment combination. However, the improvement was not statistically significant, meaning the trial did not meet its primary endpoint.
The global trial enrolled 1,371 patients. AstraZeneca said the safety profile of the combination was consistent with the known safety profiles of the medicines, with no new safety concerns identified.
The setback comes only days after the US Food and Drug Administration granted accelerated approval to Etcamah in combination with a CDK4/6 inhibitor for certain patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer whose tumours have an ESR1 mutation.
Editorial Analysis
Why This Matters
The result is significant because a successful trial could have expanded Etcamah’s use to a broader group of breast cancer patients. The drug, however, already has regulatory approval for a specific ESR1-mutated patient population.
AstraZeneca said the full SERENA-4 trial data will be presented at an upcoming medical meeting.
